|
|
|
|
|
Part the Cloud Challenge on Inflammation Grant Recipients
Isidro Ferrer, M.D., Ph.D.
Bellvitge Biomedical Research Institute Barcelona, Spain
Proposes a Phase II clinical trial to examine if Sativex reduces brain inflammation and helps slow the progression of Alzheimer's disease in people with mild cognitive impairment who may be at an increased risk for developing Alzheimer's.
John M. Olichney, M.D. University of California, Davis
Proposes a Phase II clinical trial which will examine if the drug Senicapoc reduces brain inflammation and slows or prevents progression of Alzheimer's disease.
Anthony Andrew Oliva, Ph.D. Longeveron, LLC Miami, FL
Proposes a Phase I clinical study of whether (Adult) Mesenchymal Stem Cell Therapy for Neuroinflammation is safe and able to reduce brain inflammation in people with early Alzheimer's disease.
Huntington Potter, Ph.D. University of Colorado, Denver
Proposes Phase II clinical trial to determine if the FDA-approved cancer drug, Leukine, is able to be repurposed as a safe and effective treatment to slow or prevent the progression of Alzheimer's. |
|
|
|
2015 PTC Awardee Tim West in Final Stages of Testing Tau Antibody
Dr. Tim West, a 2015 PTC awardee, and the team at C2N are in the final stages of testing an additional dosage of their tau antibody. We expect this study to report out in the coming months on whether the experimental drug will move forward. Dr. West and his team have partnered with Abbvie so if their Phase 1 is successful, they will move into phase 2 quickly. Learn more. |
|
|
|
Additional PTC Grant Recipient Updates
- A trial led by Dr. Whitney Wharton, a 2015 PTC awardee at Emory University, looking at a drug used for cardiovascular disease in people with Alzheimer's disease has started to recruit individuals for their trial. Further, in collaboration with Dr. Malu Tansey, Dr. Wharton received a large NIH award of over $3 million to add additional outcomes of inflammation from blood and cerebrospinal fluid to their Part the Cloud trial.
- Dr. Ahmed Salehi, a 2013 PTC awardee, and his team in another avenue of investigation have partnered with AC Immune, to establish a trial of their antibody ACI-24 vaccine targeting beta-amyloid in people with Down Syndrome to treat Alzheimer's disease. Learn more.
- Dr. Stephen Cunnane, a 2014 PTC awardee, participated in a debate in the journal Scientific American on how access to shellfish as a food source helped the evolution of the human brains. Learn more.
|
|
|